Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorec... (

HOME >> BIOLOGY >> TECHNOLOGY

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

Date:10/22/2008

- Updated Preliminary Results Presented at 20th EORTC-NCI-AACR Symposium -

SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced positive incremental data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen (FOLFOX). In addition, results continue to suggest that both regimens have similar anti-tumor activity in first-line metastatic CRC.

"Picoplatin appears to be an active platinum in colorectal cancer without the neurotoxicity of the other active platinum agents," said Richard Goldberg, M.D., associate director of clinical research for the University of North Carolina Comprehensive Center and physician-in-chief of the N.C. Cancer Hospital. Dr. Goldberg also is a member of Poniard's Clinical Advisory Board. "These early results may support a Phase 3 trial."

The data were presented in a poster session (abstract #210/poster #210) during the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer" in Geneva, Switzerland. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of multiple solid tumor indications.

Phase 2 CRC Trial
'/>"/>

0

GOOD

Post Your Comments:

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorec...( - Updated Preliminary Results Presen...)